10/22/2019
Alexander KHUDOTEPLY/AFP/Getty Images

Pfizer is the sole US manufacturer of pediatric cancer drug vincristine since Teva discontinued production, and treatment centers such as Texas Children's Hospital and the MD Anderson Cancer Center are concerned that available doses may need to be rationed. Vincristine deliveries are scheduled to resume by late October, but the shortage may last into December, according to the FDA.

Related Summaries